Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
NCT05458219Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Oct 2022
- Primary completion
- Jun 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of arcotatug tavatecan in solid tumor, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 2 more (2 arms), sponsored by Innovent Biologics. Primary endpoints: Adverse Events, Dose-limiting Toxicity and 2 more. Started Oct 2022; status: recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction adenocarcinomapancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05458219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458219.